Treating Blood Cancers Podcast By Blood Cancer United cover art

Treating Blood Cancers

Treating Blood Cancers

By: Blood Cancer United
Listen for free

Podcast Series for Professionals by Blood Cancer UnitedTreating Blood Cancers Podcast Series - Blood Cancer United Hygiene & Healthy Living Natural History Nature & Ecology Physical Illness & Disease Science
Episodes
  • Optimizing Outcomes in Myeloma

    Optimizing Outcomes in Myeloma
    Mar 24 2026

    Amy Pierre, MSN, ANP-BC, Flatiron Health and Memorial Sloan Kettering, New York, NY and Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC

    Recorded on March 10, 2026


    Amy Pierre, MSN, ANP-BC
    Senior Clinical Director, Research Oncology, Flatiron Health
    Nurse Practitioner, Memorial Sloan Kettering Cancer Center
    New York, NY
    Peter Voorhees, MD
    Director, Outreach for Hematologic Malignancies, Plasma Cells Disorder
    Program, Department of Hematologic Oncology and Blood Disorders
    Levine Cancer Institute
    Charlotte, NC
    Professor, Cancer Medicine
    Wake Forest University School of Medicine
    Winston-Salem, NC
    In this episode, Dr. Peter Voorhees from the Levine Cancer Institute and Amy Pierre, MSN, RN, ANP BC from Flatiron Health and Memorial Sloan Kettering, break down the evolving landscape of myeloma, from early signs and diagnostic criteria to frontline therapy, transplant decisions, and T- cell redirecting therapies. They explore real world challenges in survivorship, treatment toxicity, and disparities in access to advanced therapies, offering practical insights to help care teams support patients more effectively. Tune in for an informative and forward looking discussion shaping the future of myeloma management.

    Blood Cancer United Resources:

    • Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
    • Blood Cancer United Resources for Patients
    Show more Show less
    40 mins
  • Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology

    Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology
    Mar 3 2026

    Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC

    Recorded on February 19, 2026


    Matthew Kutny, MD
    Professor of Pediatrics
    Director, Leukemia, Lymphoma and Histiocytosis Program
    Director, Pediatric Clinical Trials Office
    Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN)
    Pediatric Hematology and Oncology
    University of Alabama at Birmingham
    Birmingham, AL
    Julie Guillot
    Pediatric AML parent, global advocate, and Blood Cancer United Volunteer
    Kelly Laschinger, MSN, RN, CPNP, CPHON
    Director, Clinical Trial Support Center
    Blood Cancer United
    Washington, DC
    In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access!

    Blood Cancer United Resources:

    • Clinical Trial Support Center
    • Information Resource Center
    • Dare to Dream Project
    • Pediatric Acute Leukemia Master Clinical Trial (PedAL)

    Mentioned on this episode:

    • Project Facilitate

    This episode is supported by the Tom Reich Educational Endowment Fund.
    Show more Show less
    40 mins
  • What’s New and What’s Next in CLL

    What’s New and What’s Next in CLL
    Feb 17 2026

    Brad Kahl, MD, Siteman Cancer Center, St. Louis MO

    Recorded on January 27, 2026


    Brad Kahl, MD
    Professor of Medicine
    Division of Oncology, Department of Medicine
    Washington University School of Medicine
    Director, Lymphoma Program
    Siteman Cancer Center
    St. Louis, MO
    In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion!

    Additional Blood Cancer United Resources:

    • Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
    • Blood Cancer United Resources for Patients
    Show more Show less
    39 mins
No reviews yet